论文部分内容阅读
能玉红(Indirubin)是中药青黛中的一种成分,属吲哚类。1978年中国医学科学院血液学研究所等单位首次报导应用靛玉红治疗慢性粒细胞白血病(以下简称慢粒),并取得良好效果,国外尚未见用此药治疗白血病的报导。我们从1978年末参加了靛玉红治疗慢粒的协作组,到1979年10月共治疗10例慢粒,现将初步疗效总结如下。治疗对象所有10例慢粒均系住院患者,均经临床、血象及骨髓象检查所确诊,其中男性6例,女性4例,年令17～55岁,以青壮年为多,治疗前病程自2个月至1年不等。10例中5例为初发病例,入院前未曾用过任何化学药物。另5例为复发病例,
Indirubin (Indirubin) Indigo is a component of traditional Chinese medicine indigo. In 1978, the Institute of Hematology, Chinese Academy of Medical Sciences and other units for the first time reported the use of indirubin treatment of chronic myeloid leukemia (hereinafter referred to as CML), and achieved good results, the drug has not yet been seen in the treatment of leukemia abroad. We participated in the co-operation group of indirubin in the treatment of CML from the end of 1978, and treated 10 cochlear in October 1979. The preliminary results are summarized as follows. All 10 CML patients were hospitalized, all of whom were diagnosed by clinical, blood and bone marrow examination, including 6 males and 4 females, aged 17-55 years, with young adults as the predominant period before treatment 2 months to 1 year range. Of the 10 cases, 5 were newly diagnosed and had never received any chemical before admission. The other 5 cases of recurrent cases,